Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones.

Bruni R, Marcantonio C, Tritarelli E, Tataseo P, Stellacci E, Costantino A, Villano U, Battistini A, Ciccaglione AR.

BMC Genomics. 2011 Oct 4;12:485. doi: 10.1186/1471-2164-12-485.

2.

Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones.

Ciccaglione AR, Marcantonio C, Tritarelli E, Tataseo P, Ferraris A, Bruni R, Dallapiccola B, Gerosolimo G, Costantino A, Rapicetta M.

BMC Genomics. 2008 Jun 30;9:309. doi: 10.1186/1471-2164-9-309.

3.

Effect of ribavirin and interferon beta on miRNA profile in the hepatitis C virus subgenomic replicon-bearing Huh7 cells.

Gong BD, Xie Q, Xiang XG, Wang L, Zhao GD, An FM, Wang H, Lin LY, Yu H, Bao SS.

Int J Mol Med. 2010 Jun;25(6):853-9.

PMID:
20428788
4.

ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.

Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K.

J Hepatol. 2011 Jul;55(1):11-8. doi: 10.1016/j.jhep.2010.10.017. Epub 2010 Nov 29.

PMID:
21145867
5.

Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE.

Antiviral Res. 2005 Jan;65(1):23-34.

PMID:
15652968
6.

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Huang P, Goff DA, Huang Q, Martinez A, Xu X, Crowder S, Issakani SD, Anderson E, Sheng N, Achacoso P, Yen A, Kinsella T, Darwish IS, Kolluri R, Hong H, Qu K, Stauffer E, Goldstein E, Singh R, Payan DG, Lu HH.

Antimicrob Agents Chemother. 2008 Apr;52(4):1419-29. doi: 10.1128/AAC.00525-07. Epub 2008 Jan 28.

7.

Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.

Horscroft N, Bellows D, Ansari I, Lai VC, Dempsey S, Liang D, Donis R, Zhong W, Hong Z.

J Virol. 2005 Mar;79(5):2788-96.

8.

Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.

Jia Y, Wei L, Jiang D, Wang J, Cong X, Fei R.

J Gastroenterol Hepatol. 2007 Aug;22(8):1278-85. Epub 2007 Jun 12.

PMID:
17565587
9.

cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells.

Abe K, Ikeda M, Dansako H, Naka K, Shimotohno K, Kato N.

Virus Res. 2005 Jan;107(1):73-81.

PMID:
15567036
10.

Effect of alpha interferon on the hepatitis C virus replicon.

Guo JT, Bichko VV, Seeger C.

J Virol. 2001 Sep;75(18):8516-23.

11.

Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.

Namba K, Naka K, Dansako H, Nozaki A, Ikeda M, Shiratori Y, Shimotohno K, Kato N.

Biochem Biophys Res Commun. 2004 Oct 8;323(1):299-309.

PMID:
15351737
12.

[Influence of miR-122 on IFN-α treatment for HCV infection].

Li SJ, Chen Z, Zhu HH.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011 Nov;40(6):588-92, 652. Chinese.

PMID:
22190517
13.

Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.

Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA, Crawford JM, Nelson DR, She JX, Liu C.

Hepatology. 2003 May;37(5):1180-8.

PMID:
12717400
14.

Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.

Hiasa Y, Kuzuhara H, Tokumoto Y, Konishi I, Yamashita N, Matsuura B, Michitaka K, Chung RT, Onji M.

Hepatology. 2008 Jul;48(1):59-69. doi: 10.1002/hep.22289.

PMID:
18459156
15.

MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis.

Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, Doros A, Gerlei Z, Nagy P, Schaff Z, Kiss A.

J Gastroenterol Hepatol. 2014 Jan;29(1):121-7. doi: 10.1111/jgh.12362.

PMID:
24033414
16.

Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome.

Trejo-Avila L, Elizondo-González R, Trujillo-Murillo Kdel C, Zapata-Benavides P, Rodríguez-Padilla C, Rivas-Estilla AM.

Ann Hepatol. 2007 Jul-Sep;6(3):174-80.

PMID:
17786145
17.

Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.

Lin HM, Wang JC, Hu HS, Wu PS, Yang CC, Wu CP, Pu SY, Hsu TA, Jiaang WT, Chao YS, Chern JH, Yeh TK, Yueh A.

Antimicrob Agents Chemother. 2012 Jan;56(1):44-53. doi: 10.1128/AAC.00599-11. Epub 2011 Oct 17.

18.

Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.

Van den Eynde E, Quer J, Cubero M, Curran A, Homs M, Garcia-Cehic D, Falco V, Ribera E, Esteban JI, Pahissa A, Crespo M.

Antivir Ther. 2011;16(6):887-93. doi: 10.3851/IMP1861.

PMID:
21900721
19.

Isolation and gene analysis of interferon alpha-resistant cell clones of the hepatitis C virus subgenome.

Noguchi T, Otsubaki T, Ando I, Ogura N, Ikeda S, Shimotohno K.

Virology. 2008 Jun 5;375(2):424-32. doi: 10.1016/j.virol.2008.02.009. Epub 2008 Mar 18.

20.

Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector.

Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR.

Hepatology. 2005 Sep;42(3):702-10.

PMID:
16108059

Supplemental Content

Support Center